What did BMO change on February 06, 2026 for Biogen?

BMO Capital maintained a **Market Perform** rating for Biogen Inc. and raised its price target to **$196** from **$165** on February 06, 2026. The action keeps the rating steady while increasing the implied upside.

How should investors interpret a Market Perform rating?

Market Perform signals the analyst expects the stock to perform in line with the market or peers. It is neutral, implying limited expected outperformance while acknowledging fair valuation compared with current assumptions.

Does the price target change mean Biogen is a buy now?

A higher price target increases potential upside, but a maintained Market Perform indicates caution. Investors should compare the **$196** target with their own return requirements and Biogen’s 2026 guidance before acting.

Where can I read the analyst note and latest company guidance?

BMO’s price target change was reported by TheFly and is summarized here [source](https://thefly.com/permalinks/entry.php/id4287731/0161286394/BIIB-Biogen-price-target-raised-by--at-BMO-Capital-heres-why). Recent company guidance and earnings recap are available on Seeking Alpha [source](https://see

Analyst Ratings

BMO Capital Maintains Market Perform on Biogen Inc. (BIIB) Feb 06, 2026

ByDanny Kontos February 7, 2026February 7, 2026

BMO Capital on February 06, 2026 maintained a Market Perform rating on Biogen Inc. (BIIB) and raised its price target to $196 from $165. This BIIB analyst rating keeps BMO’s stance neutral while increasing implied upside, signaling that the firm sees improved fundamentals but not yet a clear catalyst for an outperform call. Investors should weigh the price target change against Biogen’s guidance, pipeline timing, and recent earnings commentary.